References
- Berry, G., Kitchin, R., and Mock, P. (1991), “A Comparison of Two Simple Hazard Ratio Estimators Based on the Logrank Test,” Statistics in Medicine, 10, 749–755.
- Chen, T. (2013), “Statistical Issues and Challenges in Immuno-Oncology,” Journal for ImmunoTherapy of Cancer, 1, 1–9.
- Cox, D. (1972), “Regression Models and Life-Tables,” Journal of the Royal Statistical Society, Series B, 34, 187–220.
- Fine, G. (2007), “Consequences of Delayed Treatment Effects on Analysis of Time-to-Event Endpoints,” Drug Information Journal, 41, 535–539.
- Hodi, F., O’Day, S., McDermott, D., Weber, R., and Sosman, J. (2010), “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,” New England Journal of Medicine, 363, 711–723.
- Jennison, C., and Turnbull, B. (1999), Group Sequential Methods with Applications to Clinical Trials, London: Chapman and Hall/CRC.
- Lachin, J., and Foulkes, M. (1986), “Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-up, Noncompliance, and Stratification,” Biometrics, 42, 507–519.
- Mantel, N. (1966), “Evaluation of Survival Data and Two New Rank Order Statistics Arising in its Consideration,” Cancer Chemotherapy Reports, 50, 163–170.
- Peto, R., and Peto, J. (1972), “Asymptotically Efficient Rank Invariant Test Procedures,” Journal of the Royal Statistical Society, Series A, 135, 185–207.
- Schoenfeld, D. (1981), “The Asymptotic Properties of Nonparametric Tests for Comparing Survival Distributions,” Biometrika, 68, 316–319.